Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H20NO4.C2H5NO2.Cl |
| Molecular Weight | 328.79 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].NCC(O)=O.CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C
InChI
InChIKey=KNYIDCDOKIOINV-YCBDHFTFSA-N
InChI=1S/C10H19NO4.C2H5NO2.ClH/c1-5-10(14)15-8(6-9(12)13)7-11(2,3)4;3-1-2(4)5;/h8H,5-7H2,1-4H3;1,3H2,(H,4,5);1H/t8-;;/m1../s1
Levocarnitine propionate or Propionyl L-carnitine (PLC) is the propionyl ester of L-carnitine. Propionyl-L-carnitine stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activity. The free radical scavenging activity of the drug may also be beneficial. Propionyl-L-carnitine improves coagulative fibrinolytic homeostasis in vasal endothelium and positively affects blood viscosity. It exhibits a high affinity for the muscle enzyme, carnitine acyl transferase, and as such readily converts into propionyl-CoA and free carnitine. Most studies of the therapeutic use of PLC are focused on the prevention and treatment of ischemic heart disease, congestive heart failure, hypertrophic heart disease, and peripheral arterial disease. PLC is marketed under the trade name Dromos®. It is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enhancement in patients with chronic congestive heart failure. Dromos is marketed in Italy.
Originator
Sources: www.ncbi.nlm.nih.gov/pubmed/16857830http://adisinsight.springer.com/drugs/800003253
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P50416 Gene ID: 1374.0 Gene Symbol: CPT1A Target Organism: Homo sapiens (Human) |
|||
Target ID: P23786 Gene ID: 1376.0 Gene Symbol: CPT2 Target Organism: Homo sapiens (Human) |
|||
Target ID: P43155 Gene ID: 1384.0 Gene Symbol: CRAT Target Organism: Homo sapiens (Human) |
|||
Target ID: O43772 Gene ID: 788.0 Gene Symbol: SLC25A20 Target Organism: Homo sapiens (Human) |
|||
Target ID: WP408 Sources: DOI: 10.1201/b17092-12 |
|||
Target ID: CHEMBL2216739 |
|||
Target ID: WP623 Sources: DOI: 10.1201/b17092-12 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CARNITOR Approved UseCARNITOR (levocarnitine) is indicated in the treatment of primary systemic carnitine
deficiency. Launch Date1985 |
|||
| Primary | Dromos Approved UseIt is indicated for patients with peripheral arterial occlusive disorders and for exercise intolerance enchancement in patients with chronic congestive heart failure. |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
79.2 nmol/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7658356 |
330 mg 2 times / day multiple, oral dose: 330 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOCARNITINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
80.3 nmol/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7658356 |
2 g 2 times / day multiple, oral dose: 2 g route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOCARNITINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
771.4 nmol × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7658356 |
330 mg 2 times / day multiple, oral dose: 330 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOCARNITINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
779.9 nmol × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7658356 |
2 g 2 times / day multiple, oral dose: 2 g route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOCARNITINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antagonism of doxorubicin cardiotoxicity by carnitine is specific of the L-diasteroisomer. | 1981 May |
|
| Modulation of ethanol-mediated CYP2E1 induction by clofibrate and L-carnitine in rat liver. | 1993 Dec |
|
| Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. | 1994 Apr |
|
| Contrasting effects of propionate and propionyl-L-carnitine on energy-linked processes in ischemic hearts. | 1994 Aug |
|
| Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro. | 1994 Jul |
|
| Muscle carnitine deficiency associated with zidovudine-induced mitochondrial myopathy. | 1994 Oct |
|
| Effect of L-carnitine supplementation on acute valproate intoxication. | 1996 Jul |
|
| L-carnitine supplementation in patients with cystic acne on isotretinoin therapy. | 1999 Nov |
|
| Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection. | 2002 Jul |
|
| Analysis of carnitine biosynthesis metabolites in urine by HPLC-electrospray tandem mass spectrometry. | 2002 Jun |
|
| Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. | 2003 Jun |
|
| Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. | 2004 May |
|
| Carnitine: a nutritional, biosynthetic, and functional perspective. | 2004 Oct-Dec |
|
| Fatty acid oxidation defects as a cause of neuromyopathic disease in infants and adults. | 2005 |
|
| Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. | 2005 Jan |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
| Sodium valproate -- induced skeletal myopathy. | 2005 Mar |
|
| Ammonia-mediated LTP inhibition: effects of NMDA receptor antagonists and L-carnitine. | 2005 Nov |
|
| Involvement of recognition and interaction of carnitine transporter in the decrease of L-carnitine concentration induced by pivalic acid and valproic acid. | 2006 Aug |
|
| Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells. | 2006 Nov |
|
| Carnitine deficiency aggravates carboplatin nephropathy through deterioration of energy status, oxidant/anti-oxidant balance, and inflammatory endocoids. | 2008 Dec 5 |
|
| High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. | 2008 Jun |
|
| L-carnitine mediates protection against DNA damage in lymphocytes of aged rats. | 2009 Apr |
|
| Carnitine deficiency: a possible risk factor in paracetamol hepatotoxicity. | 2009 Feb |
|
| Increased urinary losses of carnitine and decreased intramitochondrial coenzyme A in gentamicin-induced acute renal failure in rats. | 2010 Jan |
|
| The plasma carnitine concentration regulates renal OCTN2 expression and carnitine transport in rats. | 2010 Jun 10 |
|
| Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. | 2011 Apr |
|
| Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. | 2011 Jun |
|
| The disruption of L-carnitine metabolism by aluminum toxicity and oxidative stress promotes dyslipidemia in human astrocytic and hepatic cells. | 2011 Jun 24 |
|
| L-carnitine protects against nickel-induced neurotoxicity by maintaining mitochondrial function in Neuro-2a cells. | 2011 May 15 |
|
| Bezafibrate upregulates carnitine palmitoyltransferase II expression and promotes mitochondrial energy crisis dissipation in fibroblasts of patients with influenza-associated encephalopathy. | 2011 Nov |
|
| Downregulation of oxidative and nitrosative apoptotic signaling by L-carnitine in Ifosfamide-induced Fanconi syndrome rat model. | 2012 |
|
| L-Carnitine rescues ketamine-induced attenuated heart rate and MAPK (ERK) activity in zebrafish embryos. | 2012 Apr |
|
| Propionyl-L-Carnitine Enhances Wound Healing and Counteracts Microvascular Endothelial Cell Dysfunction. | 2015 |
|
| Changes in the levels of l-carnitine, acetyl-l-carnitine and propionyl-l-carnitine are involved in perfluorooctanoic acid induced developmental cardiotoxicity in chicken embryo. | 2016 Dec |
|
| Inflammatory and fibrotic processes are involved in the cardiotoxic effect of sunitinib: Protective role of L-carnitine. | 2016 Jan 22 |
Patents
Sample Use Guides
Adults: The recommended oral dosage for adults is 990 mg two or three times a day using the 330 mg tablets, depending on clinical response. Infants and children: The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
423152-20-9
Created by
admin on Sat Dec 16 18:16:00 GMT 2023 , Edited by admin on Sat Dec 16 18:16:00 GMT 2023
|
PRIMARY | |||
|
Glycine propionyl-L-carnitine
Created by
admin on Sat Dec 16 18:16:00 GMT 2023 , Edited by admin on Sat Dec 16 18:16:00 GMT 2023
|
PRIMARY | |||
|
87549923
Created by
admin on Sat Dec 16 18:16:00 GMT 2023 , Edited by admin on Sat Dec 16 18:16:00 GMT 2023
|
PRIMARY | |||
|
LY38SJU4DG
Created by
admin on Sat Dec 16 18:16:00 GMT 2023 , Edited by admin on Sat Dec 16 18:16:00 GMT 2023
|
PRIMARY | |||
|
DTXSID901029527
Created by
admin on Sat Dec 16 18:16:00 GMT 2023 , Edited by admin on Sat Dec 16 18:16:00 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
